Gilead Sciences, Inc., a leading biopharmaceutical company headquartered in the United States, has been at the forefront of innovative healthcare since its founding in 1987. With a strong presence in regions such as Europe and Asia, Gilead focuses on the research, development, and commercialisation of antiviral drugs, particularly for HIV, hepatitis B, hepatitis C, and influenza. The company is renowned for its groundbreaking therapies, including Biktarvy and Harvoni, which have transformed the treatment landscape for chronic viral infections. Gilead's commitment to advancing medicine is underscored by its significant achievements, including multiple FDA approvals and a robust pipeline of investigational therapies. As a key player in the biopharmaceutical industry, Gilead Sciences continues to shape the future of healthcare through its dedication to scientific innovation and patient care.
How does Gilead Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Gilead Sciences's score of 53 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Gilead Sciences reported total carbon emissions of approximately 1,179,798,000 kg CO2e, comprising 56,096,000 kg CO2e from Scope 1, 22,339,000 kg CO2e from Scope 2, and 1,121,798,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 46% by 2030, using 2019 as the base year. Additionally, Gilead plans to cut its absolute Scope 3 emissions by 15% over the same timeframe. Over the years, Gilead's emissions have fluctuated, with Scope 1 emissions peaking at 54,098,000 kg CO2e in 2019 and Scope 2 emissions reaching a high of 52,526,000 kg CO2e in 2020. The company has disclosed emissions data across all three scopes, demonstrating a commitment to transparency in its environmental impact. Gilead's targets align with the Science Based Targets initiative (SBTi), reflecting its commitment to limiting global warming to 1.5°C. The company continues to focus on reducing its carbon footprint while maintaining its position in the pharmaceuticals, biotechnology, and life sciences sector.
Access structured emissions data, company-specific emission factors, and source documents
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|
Scope 1 | 44,754,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 29,127,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 32,003,000 | 00,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gilead Sciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.